These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29702001)

  • 41. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
    Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
    Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
    Advani AS; Li H; Michaelis LC; Medeiros BC; Liedtke M; List AF; O'Dwyer K; Othus M; Erba HP; Appelbaum FR
    Leuk Res; 2018 Apr; 67():17-20. PubMed ID: 29407182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
    Wiedower E; Jamy O; Martin MG
    Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
    Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
    J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.
    Kim T; Moon JH; Ahn JS; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Tyndel MS; Shin MG; Lee YJ; Sohn SK; Park SK; Zhang Z; Kim HJ; Kim DDH
    Blood; 2018 Oct; 132(15):1604-1613. PubMed ID: 30108064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
    Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
    J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
    Feng X; Lan H; Ruan Y; Li C
    Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.